A randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, safety, tolerability and efficacy of omiganan BID in patients with mild to moderate atopic dermatitis
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Omiganan (Primary)
- Indications Atopic dermatitis
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Cutanea Life Sciences
- 15 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 15 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
- 18 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.